-
Trump renames AI 'super intelligence' as leaders jostle over dangers
-
Man City hold Bayern to start Women's Champions League, Arsenal win late
-
Oil prices retreat as markets welcome US-Iran talks
-
Trump threatens Iran with 'hell' but reveals fresh talks
-
US refusing to give Sudan's de facto leader visa for UN: diplomatic sources, UN
-
Trump signs security deal with Greenland, Denmark at UN
-
Macron urges world to choose UN over 'law of the jungle'
-
Trump threatens Iran with 'hell' but unveils fresh talks
-
All-rounder Jacks stars as England beat Sri Lanka in 1st ODI
-
Chile's Atacama Desert blossoms with life after El Nino rains
-
Man City peg back Bayern to start Women's Champions League
-
Sri Lanka hands 220-year jail terms to 15 convicted of Easter bombings
-
Trump beats 'America first' drum at UN as allies tread carefully
-
Typhoon Dujuan leaves 7 dead in Japan from landslides, flooding: media
-
Snedeker backs Spaun for Ryder Cup after Presidents snub
-
Ganna and Borghini lead Italy to mixed relay gold at cycling worlds
-
French prosecutors probe secret filming of women with smart glasses
-
Drug cocktail killed former child star Hayden Panettiere: coroner
-
Trump renames AI "super intelligence," rejects international oversight
-
Moldova declares energy, water emergency
-
Trump rejects international regulation of AI
-
French Holocaust denier jailed for eight months
-
How is the EU approaching record fuel prices?
-
Oil prices slide, AI stock buzz fades
-
Sri Lanka's Colombage strikes on debut as England dismissed for 265 in first ODI
-
Trump threatens to 'annihilate' Iran in bombastic UN speech
-
Hurricane Polo strengthens to top category 5 off Mexico
-
Prada's skirts take centre stage as Milan Fashion Week begins
-
11 hurt as teen opens fire outside school in western Turkey
-
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
-
UN chief says 'Big Oil' treats atmosphere as open sewer
-
Brazil's Flavio Bolsonaro turns scandal into poll gains
-
Tunisia says 2026 summer hottest on record
-
Republican senator seeks probe of Trump Jr Russian-funded wedding
-
England's Rashid out of Sri Lanka ODIs with hand injury
-
Memoir by Diana's brother goes on sale after rocking UK monarchy
-
Houthis accuse Saudi Arabia of deadly strikes as thousands flee
-
Newcomers South Korea face holders Italy in Davis Cup finals
-
Stocks climb as oil slides, AI buzz returns
-
Japan's Kojima sounds Marchand warning with Asian Games gold
-
India cricketers win in style as Afghan savours 'special' Games silver
-
England rugby star Pollock signs new Northampton deal
-
La Liga president hits out at Real Madrid refereeing 'conspiracy' claims
-
STARTRADER Expands Its Chinese Equity CFD Range with CXMT and Unitree Robotics
-
MEXC Launches “Real Stocks, Real Friends” with Rewards for Bringing Friends to Wall Street
-
MEXC Expands Opportunity Compass with Stock Trading Handbook to Help Crypto Users Build Investment Knowledge
-
Mbappe continues media push for Ballon d'Or recognition
-
England paceman Wood retires from international cricket
-
Stocks rise on AI buzz, oil prices cool
-
Magnificent Mandhana's 79 helps India to Asian Games cricket gold
Abortion pill under threat in Texas court case
US abortion opponents are hoping for a national ban on a widely used abortion pill when their lawsuit against government drug regulators is argued Wednesday in the Texas court of a deeply conservative judge believed to be sympathetic to their cause.
Galvanized after the US Supreme Court ended the nationwide right to abortion last June, anti-abortion forces are now targeting the prescription drug mifepristone in their campaign to win a total ban on the practice.
The suit against the US Food and Drug Administration (FDA) aims at a pill involved in 53 percent of all abortions in the United States, or more than a half-million every year.
While the FDA has never been challenged like this before on its approval of a drug that has proven safe and effective, the plaintiffs, a coalition of anti-abortion groups, believe they can win a national freeze on distribution of mifepristone.
Presiding over the case in federal court in Amarillo, Texas will be Judge Matthew Kacsmaryk, a deeply conservative Christian with a personal history of opposition to abortion and a court record of favoring right-wing causes.
The case ended up in his court via what critics call "judge-shopping," in which plaintiffs take legal action in a district where the judge has a history of rulings that support their case.
- Record of safety -
One component of a two-drug regimen used for medication abortion, mifepristone can be used in the United States up to 10 weeks of pregnancy.
It has a long safety record, and the FDA estimates 5.6 million Americans have used it to terminate pregnancies since it was approved.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying the approval of mifepristone "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with its use.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
- Already banned in some states -
Currently, some 15 states have laws restricting access to mifepristone by requiring a physician provide it, according to the Guttmacher Institute, a reproductive health policy and research group. Abortion care has halted in another 13 states after the Supreme Court overturned the long-established constitutional right last June.
The Texas suit seeks to block mifepristone nationally by overturning the FDA's approval of the drug, and asks Kacsmaryk to first suspend the approval via injunction -- an effective ban -- while the lawsuit proceeds through his court.
Abortion rights groups say a ruling blocking mifepristone would be as earth-shaking as the Supreme Court's ruling last year.
"Access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
If Kacsmaryk does rule for a temporary ban on mifepristone, the FDA would likely immediately appeal it, on the basis of the drug's history and its own authority to regulate pharmaceuticals.
But abortion rights advocates were preparing for the worst.
"It seems unbelievable that a lone judge in Texas could make a ruling that would impact a product that has been FDA approved and safely marketed for more than two decades," said Elisa Wells, co-founder of Plan C, which helps people access medical abortions.
L.Mesquita--PC